Esperion Therapeutics Inc. (NASDAQ:ESPR) received a $13.00 price objective from equities researchers at Chardan Capital in a report issued on Thursday. The brokerage currently has a a “hold” rating on the biopharmaceutical company’s stock. Chardan Capital’s price objective points to a potential upside of 5.52% from the company’s previous close.

A number of other research firms have also commented on ESPR. JMP Securities reaffirmed a “buy” rating and issued a $67.00 price objective on shares of Esperion Therapeutics in a research note on Thursday, June 16th. Credit Suisse Group AG lowered shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and reduced their price objective for the company from $23.00 to $10.00 in a research note on Wednesday, June 29th. Lake Street Capital reduced their price objective on shares of Esperion Therapeutics from $80.00 to $27.00 and set a “buy” rating on the stock in a research note on Wednesday, June 29th. Royal Bank Of Canada lowered shares of Esperion Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price objective for the company from $30.00 to $15.00 in a research note on Wednesday, June 29th. Finally, JPMorgan Chase & Co. lowered shares of Esperion Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $50.00 to $15.00 in a research note on Wednesday, June 29th. One research analyst has rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $28.54.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR) traded up 5.28% on Thursday, reaching $12.97. 1,228,796 shares of the company were exchanged. The company’s 50-day moving average price is $12.23 and its 200-day moving average price is $13.99. The stock’s market capitalization is $292.47 million. Esperion Therapeutics has a 12-month low of $9.58 and a 12-month high of $30.41.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.78) by $0.16. During the same quarter in the prior year, the business earned ($0.55) earnings per share. Equities research analysts anticipate that Esperion Therapeutics will post ($3.37) earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of Esperion Therapeutics by 17.8% in the first quarter. Geode Capital Management LLC now owns 107,392 shares of the biopharmaceutical company’s stock worth $1,815,000 after buying an additional 16,208 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Esperion Therapeutics during the first quarter worth about $313,000. A.R.T. Advisors LLC increased its stake in shares of Esperion Therapeutics by 93.6% in the first quarter. A.R.T. Advisors LLC now owns 200,858 shares of the biopharmaceutical company’s stock worth $3,396,000 after buying an additional 97,112 shares during the last quarter. Bellevue Group AG purchased a new stake in shares of Esperion Therapeutics during the first quarter worth about $676,000. Finally, BVF Inc. IL purchased a new stake in shares of Esperion Therapeutics during the first quarter worth about $10,261,000. 65.22% of the stock is currently owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

5 Day Chart for NASDAQ:ESPR

Receive News & Stock Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related stocks with our FREE daily email newsletter.